{"filing":{"accession_number":"0001213900-26-099738","cik":"0002028614","ticker":"DMAAR","company_name":"Drugs Made In America Acquisition Corp.","form":"8-K","filing_date":"2026-09-14","report_date":"2026-09-08","primary_document":"ea0305461-8k425_drugs.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2028614/000121390026099738/ea0305461-8k425_drugs.htm"},"events":[{"id":33322,"run_id":30633,"accession_number":"0001213900-26-099738","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"summary":"The filing discloses entry into an Amended and Restated Definitive Merger Agreement on September 8, 2026, between DMAA and Power Analytics Global Corp (PAGC), with a fixed Closing Valuation of US$2,850,000,000. This is a material acquisition/merger transaction that restructures the blank-check company into a publicly traded holding company, directly triggering Item 1.01 disclosure requirements and materially affecting investor assessment of the registrant's future.","company_name":"Drugs Made In America Acquisition Corp.","ticker":"DMAAR","filing_date":"2026-09-14","form":"8-K","submitted_at":null,"items":[{"id":36738,"accession_number":"0001213900-26-099738","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"The filing discloses entry into an Amended and Restated Definitive Merger Agreement on September 8, 2026, between DMAA and Power Analytics Global Corp (PAGC), with a fixed Closing Valuation of US$2,850,000,000. This is a material acquisition/merger transaction that restructures the blank-check company into a publicly traded holding company, directly triggering Item 1.01 disclosure requirements and materially affecting investor assessment of the registrant's future.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T20:36:58.372379+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36738,"accession_number":"0001213900-26-099738","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"The filing discloses entry into an Amended and Restated Definitive Merger Agreement on September 8, 2026, between DMAA and Power Analytics Global Corp (PAGC), with a fixed Closing Valuation of US$2,850,000,000. This is a material acquisition/merger transaction that restructures the blank-check company into a publicly traded holding company, directly triggering Item 1.01 disclosure requirements and materially affecting investor assessment of the registrant's future.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T20:36:58.372379+00:00","company_name":"Drugs Made In America Acquisition Corp.","ticker":"DMAAR","filing_date":"2026-09-14"}]}